

Grifols strengthens its position among the world's most sustainable biotechnology companies after improving its Dow Jones Best-in-Class score

- *The company reaffirms its inclusion in the Dow Jones Best-in-Class World and Dow Jones Best-in-Class Europe indices for the fifth and sixth consecutive years, respectively*
- *Grifols increases its overall score and achieves the highest possible rating in key areas such as Transparency and Reporting, Business Ethics, Information Security and Climate Strategy*
- *Governance is the ESG dimension with the greatest improvement, increasing by nine points*

Barcelona, Spain, May 4, 2026 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, has strengthened its position among the world's most sustainable biotechnology companies after improving its score in the Dow Jones Best-in-Class indices and marking five and six consecutive years of inclusion in their World and Europe versions, respectively. The company achieved a score of 74 points, four more than the previous year, consolidating its position as one of the global benchmarks in sustainability within the sector.

The company delivered solid performance across the three ESG dimensions (Environmental, Social and Governance). Grifols achieved the highest possible score, 100 points, in key areas such as Transparency and Reporting, Business Ethics, Information Security and Climate Strategy. It also maintains a strong position in the 83rd percentile in areas such as Product Quality and Recall Management, Energy Management, Human Rights and global Governance. In Governance, the company stands out for a nine-point improvement compared to the previous year. This concentration in the highest percentiles reflects strong and balanced sustainability performance, clearly differentiating Grifols from its peer group.

The company's progress compared to previous assessments has been driven by double-digit improvements in strategic areas. The most notable increases were recorded in Information Security and Product Quality and Recall Management, both rising by 26 points. Overall, these results demonstrate consistent and measurable progress in governance, operational excellence and environmental management.

The Dow Jones Best-in-Class indices include global sustainability leaders identified by S&P Global through its Corporate Sustainability Assessment. In the latest edition, 335 biotechnology companies worldwide were evaluated for their ESG performance following a rigorous comparative analysis process. Grifols' inclusion in these indices reflects the company's commitment to integrating responsible practices across all its operations, effectively managing ESG risks and opportunities, and contributing to a more sustainable and resilient healthcare industry.

This achievement adds to other recent recognitions that position Grifols among the top-performing companies in sustainability. Recently, the company achieved Platinum status, the highest distinction, in EcoVadis' sustainability rating. Grifols also received Prime status in ISS ESG ratings, a BB rating

in MSCI ESG Ratings, and was ranked among the top companies by Sustainalytics with a low ESG risk rating. The company also participates annually in the Carbon Disclosure Project (CDP).

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols focuses on treating conditions centered on six core therapeutic areas: immunology, neurology, pulmonology, hematology, hepatology and intensive care.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's most diversified with more than 400 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 25,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the IBEX-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com

MEDIA CONTACTS:

Grifols Press Office

media@grifols.com

Phone: +34 93 571 00 02

INVESTORS:

Investor Relations & Sustainability

investors@grifols.com – inversores@grifols.com

sustainability@grifols.com – sostenibilidad@grifols.com

Phone: +34 93 571 02 21

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are 'projections and future hypotheses'. Words and expressions such as 'believe', 'expect', 'anticipate', 'predict', 'hope', 'intend', 'should', 'will try to achieve', 'is estimated', 'future' and similar expressions, insofar as they refer to the Grifols group, are used to identify future projections and hypotheses. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a series of factors that mean that the real results may be materially different. The future results of the Grifols group could be affected by events related to its own activities, such as shortages of supplies of raw materials for the manufacture of its products, the appearance on the market of competing products, or changes in the regulatory framework of the markets in which it operates, among others. At the date of preparation of this report, the Grifols group has adopted the necessary measures to mitigate the foreseeable impact of these events. Grifols, S.A. assumes no obligation to publicly report, revise or update the projections or future hypotheses to adapt them to facts or circumstances after the date of writing of this report, except when expressly required by applicable legislation. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Law 6/2023, of 17 March, on the Securities Markets and Investment Services, and any regulations implementing said legislation. Furthermore, this document does not constitute an offer to purchase, sell or exchange, or a solicitation of an offer to purchase, sell or exchange any securities, or a solicitation of any vote or approval in any other jurisdiction. The information contained in this document has not been verified or revised by the external auditors of the Grifols group.